Abiraterone Acetate

Both abiraterone and enzalutamide appeared to increase risk for metabolic and cardiovascular adverse events among older men with advanced prostate cancer who previously underwent androgen deprivation therapy, according to study results.

Healio spoke with Daniel P. Petrylak, MD, about a presentation the American Urological Association meeting that focused on discontinuation rates of hormone therapy options among patients with advanced prostate cancer.

In this video, Daniel P. Petrylak, MD, discussed a presentation investigating androgen deprivation therapy plus upfront docetaxel in the treatment of patients 75 years or older with prostate cancer.

First-line abiraterone acetate for metastatic castration-resistant prostate cancer conferred longer OS among Black men compared with non-Hispanic white men, according to study results published in JAMA Network Open.

SAN FRANCISCO — The addition of cabazitaxel to neoadjuvant abiraterone acetate did not improve tumor response among men with high-risk prostate cancer, according to randomized phase 2 study results presented at ASCO Genitourinary Cancers Symposium.

In this video, Eugene Shenderov, MD, PhD, discusses the STAMPEDE and PEACE-1 studies, which evaluated the addition of abiraterone acetate plus prednisolone to standard therapy for patients with prostate cancer.

In this video, Ben Tran, MD, discusses the PEACE-1 and STAMPEDE studies that looked at the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy, which was found to improve survival vs. standard therapy.

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses two posters on prostate cancer therapies presented at the ESMO Congress 2021.

Two years of abiraterone acetate plus prednisolone-based therapy significantly improved survival among men with high-risk nonmetastatic prostate cancer starting androgen deprivation therapy, according to results of the STAMPEDE trial.

Adding abiraterone acetate to androgen deprivation therapy plus docetaxel improved radiographic PFS and OS among men with metastatic castration-sensitive prostate cancer, according to data presented during the virtual ESMO Congress 2021.